---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009006"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:11:44.456829+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics receives Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive days

## Summary
- Received Nasdaq staff deficiency notice on March 24, 2023.
- Closing bid price below $1.00 for 30 consecutive business days (Feb 9 to Mar 23, 2023).
- Given 180-day compliance period until September 20, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not compliant, may be eligible for additional 180-day grace period if meets other listing standards.
- Management intends to cure deficiency and continue listing on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-23-009006
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009006/0001493152-23-009006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009006/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009006
- JSON: https://secwatch.observer/filing/0001493152-23-009006.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009006.txt

## Key facts
- Listing & Compliance Notices
  Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: March 24, 2023, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (February 9, 2023 through March 23, 2023), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009006/0001493152-23-009006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.